These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 9528862)

  • 61. The protein tyrosine phosphatase SHP-2 is required for EGFRvIII oncogenic transformation in human glioblastoma cells.
    Zhan Y; Counelis GJ; O'Rourke DM
    Exp Cell Res; 2009 Aug; 315(14):2343-57. PubMed ID: 19427850
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effect and mechanism of epidermal growth factor on proliferation of GL15 gliomas cell line.
    Wang H; Guo D; Ye F; Xi G; Wang B; Chen J; Lei T
    J Huazhong Univ Sci Technolog Med Sci; 2006; 26(5):604-6. PubMed ID: 17219981
    [TBL] [Abstract][Full Text] [Related]  

  • 63. EGFRvIII undergoes activation-dependent downregulation mediated by the Cbl proteins.
    Davies GC; Ryan PE; Rahman L; Zajac-Kaye M; Lipkowitz S
    Oncogene; 2006 Oct; 25(49):6497-509. PubMed ID: 16702950
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII.
    Pedersen MW; Pedersen N; Ottesen LH; Poulsen HS
    Br J Cancer; 2005 Oct; 93(8):915-23. PubMed ID: 16189524
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Distinct domains in the SHP-2 phosphatase differentially regulate epidermal growth factor receptor/NF-kappaB activation through Gab1 in glioblastoma cells.
    Kapoor GS; Zhan Y; Johnson GR; O'Rourke DM
    Mol Cell Biol; 2004 Jan; 24(2):823-36. PubMed ID: 14701753
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Structure-based approaches to inhibition of erbB receptors with peptide mimetics.
    Berezov A; Greene MI; Murali R
    Immunol Res; 2003; 27(2-3):303-8. PubMed ID: 12857977
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Induction of the Tat-binding protein 1 gene accompanies the disabling of oncogenic erbB receptor tyrosine kinases.
    Park BW; O'Rourke DM; Wang Q; Davis JG; Post A; Qian X; Greene MI
    Proc Natl Acad Sci U S A; 1999 May; 96(11):6434-8. PubMed ID: 10339605
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells.
    O'Rourke DM; Kao GD; Singh N; Park BW; Muschel RJ; Wu CJ; Greene MI
    Proc Natl Acad Sci U S A; 1998 Sep; 95(18):10842-7. PubMed ID: 9724792
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?
    Normanno N; Maiello MR; De Luca A
    J Cell Physiol; 2003 Jan; 194(1):13-9. PubMed ID: 12447985
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Principles of receptor-based inhibition of erbB family receptor kinases: prospects for new therapies for human cancers.
    O'Rourke DM; Zhang X; Greene MI
    Proc Assoc Am Physicians; 1997 May; 109(3):209-19. PubMed ID: 9154637
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: implications for subdomain contributions to receptor assembly.
    O'Rourke DM; Nute EJ; Davis JG; Wu C; Lee A; Murali R; Zhang HT; Qian X; Kao CC; Greene MI
    Oncogene; 1998 Mar; 16(9):1197-207. PubMed ID: 9528862
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Inhibition of p185neu kinase activity and cellular transformation by co-expression of a truncated neu protein.
    Qian X; O'Rourke DM; Zhao H; Greene MI
    Oncogene; 1996 Nov; 13(10):2149-57. PubMed ID: 8950982
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The role of distinct p185neu extracellular subdomains for dimerization with the epidermal growth factor (EGF) receptor and EGF-mediated signaling.
    Kumagai T; Davis JG; Horie T; O'Rourke DM; Greene MI
    Proc Natl Acad Sci U S A; 2001 May; 98(10):5526-31. PubMed ID: 11320205
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis.
    Nagane M; Coufal F; Lin H; Bögler O; Cavenee WK; Huang HJ
    Cancer Res; 1996 Nov; 56(21):5079-86. PubMed ID: 8895767
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
    Tang CK; Gong XQ; Moscatello DK; Wong AJ; Lippman ME
    Cancer Res; 2000 Jun; 60(11):3081-7. PubMed ID: 10850460
    [TBL] [Abstract][Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.